Renal cell carcinoma: the population, real world, and cost-of-illness
Abstract Background The RCC treatment landscape has evolved dramatically over the past decade. The purpose of this study is to present a real-world data estimation of RCC’s cost-of-illness for this tumour’s clinical pathway. Methods This investigation is a population-based cohort study using real-wo...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12894-022-01160-y |
| _version_ | 1828086904690573312 |
|---|---|
| author | Alessandra Buja Giuseppe De Luca Maura Gatti Claudia Cozzolino Massimo Rugge Manuel Zorzi Mario Gardi Matteo Sepulcri Davide Bimbatti Vincenzo Baldo Marco Maruzzo Umberto Basso Vittorina Zagonel |
| author_facet | Alessandra Buja Giuseppe De Luca Maura Gatti Claudia Cozzolino Massimo Rugge Manuel Zorzi Mario Gardi Matteo Sepulcri Davide Bimbatti Vincenzo Baldo Marco Maruzzo Umberto Basso Vittorina Zagonel |
| author_sort | Alessandra Buja |
| collection | DOAJ |
| description | Abstract Background The RCC treatment landscape has evolved dramatically over the past decade. The purpose of this study is to present a real-world data estimation of RCC’s cost-of-illness for this tumour’s clinical pathway. Methods This investigation is a population-based cohort study using real-world data, which considers all RCC incident cases diagnosed in Local Unit 6 of the Province of Padua in 2016 and 2017 as registered by the Veneto Cancer Registry. Data on drug prescriptions, the use of medical devices, hospital admissions, and visits to outpatient clinics and emergency departments were collected by means of administrative databases. We evaluated the costs of all healthcare procedures performed in the 2 years of follow-up post-RCC diagnosis. The overall and annual average real-world costs per patient, both as a whole and by single item, were calculated and stratified by stage of disease at diagnosis. Results The analysis involved a population of 148 patients with a median age of 65.8 years, 66.22% of whom were male. Two years after diagnosis, the average total costs amounted to €21,429 per patient. There is a steady increment in costs with increasing stage at diagnosis, with a total amount of €41,494 spent 2 years after diagnosis for stage IV patients, which is 2.44 times higher than the expenditure for stage I patients (€17,037). In the first year, hospitalization appeared to be the most expensive item for both early and advanced disease. In the second year, however, outpatient procedures were the main cost driver in the earlier stages, whereas anticancer drugs accounted for the highest costs in the advanced stages. Conclusions This observational study provides real-world and valuable estimates of RCC’s cost-of-illness, which could enable policymakers to construct dynamic economic cost-effectiveness evaluation models based on real world costs’ evaluation. |
| first_indexed | 2024-04-11T05:04:30Z |
| format | Article |
| id | doaj.art-b7c0b6dfeb9a4ee5ad0ad00faec961ee |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-04-11T05:04:30Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-b7c0b6dfeb9a4ee5ad0ad00faec961ee2022-12-25T12:30:57ZengBMCBMC Urology1471-24902022-12-012211810.1186/s12894-022-01160-yRenal cell carcinoma: the population, real world, and cost-of-illnessAlessandra Buja0Giuseppe De Luca1Maura Gatti2Claudia Cozzolino3Massimo Rugge4Manuel Zorzi5Mario Gardi6Matteo Sepulcri7Davide Bimbatti8Vincenzo Baldo9Marco Maruzzo10Umberto Basso11Vittorina Zagonel12Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of PaduaDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of PaduaStatistics Department, University of PaduaSoft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCSDepartment of Medicine - DIMED, Pathology and Cytopathology Unit, University of PaduaVeneto Tumor Registry, Azienda ZeroUnit of Urology, Ospedale Sant’Antonio, Azienda Ospedale Università-PadovaRadiotherapy Unit, Veneto Institute of Oncology IOV-IRCCSOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCSDepartment of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of PaduaOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCSOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCSOncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCSAbstract Background The RCC treatment landscape has evolved dramatically over the past decade. The purpose of this study is to present a real-world data estimation of RCC’s cost-of-illness for this tumour’s clinical pathway. Methods This investigation is a population-based cohort study using real-world data, which considers all RCC incident cases diagnosed in Local Unit 6 of the Province of Padua in 2016 and 2017 as registered by the Veneto Cancer Registry. Data on drug prescriptions, the use of medical devices, hospital admissions, and visits to outpatient clinics and emergency departments were collected by means of administrative databases. We evaluated the costs of all healthcare procedures performed in the 2 years of follow-up post-RCC diagnosis. The overall and annual average real-world costs per patient, both as a whole and by single item, were calculated and stratified by stage of disease at diagnosis. Results The analysis involved a population of 148 patients with a median age of 65.8 years, 66.22% of whom were male. Two years after diagnosis, the average total costs amounted to €21,429 per patient. There is a steady increment in costs with increasing stage at diagnosis, with a total amount of €41,494 spent 2 years after diagnosis for stage IV patients, which is 2.44 times higher than the expenditure for stage I patients (€17,037). In the first year, hospitalization appeared to be the most expensive item for both early and advanced disease. In the second year, however, outpatient procedures were the main cost driver in the earlier stages, whereas anticancer drugs accounted for the highest costs in the advanced stages. Conclusions This observational study provides real-world and valuable estimates of RCC’s cost-of-illness, which could enable policymakers to construct dynamic economic cost-effectiveness evaluation models based on real world costs’ evaluation.https://doi.org/10.1186/s12894-022-01160-yRenal cell carcinomaCost-of-illnessEconomic impactReal-world data |
| spellingShingle | Alessandra Buja Giuseppe De Luca Maura Gatti Claudia Cozzolino Massimo Rugge Manuel Zorzi Mario Gardi Matteo Sepulcri Davide Bimbatti Vincenzo Baldo Marco Maruzzo Umberto Basso Vittorina Zagonel Renal cell carcinoma: the population, real world, and cost-of-illness BMC Urology Renal cell carcinoma Cost-of-illness Economic impact Real-world data |
| title | Renal cell carcinoma: the population, real world, and cost-of-illness |
| title_full | Renal cell carcinoma: the population, real world, and cost-of-illness |
| title_fullStr | Renal cell carcinoma: the population, real world, and cost-of-illness |
| title_full_unstemmed | Renal cell carcinoma: the population, real world, and cost-of-illness |
| title_short | Renal cell carcinoma: the population, real world, and cost-of-illness |
| title_sort | renal cell carcinoma the population real world and cost of illness |
| topic | Renal cell carcinoma Cost-of-illness Economic impact Real-world data |
| url | https://doi.org/10.1186/s12894-022-01160-y |
| work_keys_str_mv | AT alessandrabuja renalcellcarcinomathepopulationrealworldandcostofillness AT giuseppedeluca renalcellcarcinomathepopulationrealworldandcostofillness AT mauragatti renalcellcarcinomathepopulationrealworldandcostofillness AT claudiacozzolino renalcellcarcinomathepopulationrealworldandcostofillness AT massimorugge renalcellcarcinomathepopulationrealworldandcostofillness AT manuelzorzi renalcellcarcinomathepopulationrealworldandcostofillness AT mariogardi renalcellcarcinomathepopulationrealworldandcostofillness AT matteosepulcri renalcellcarcinomathepopulationrealworldandcostofillness AT davidebimbatti renalcellcarcinomathepopulationrealworldandcostofillness AT vincenzobaldo renalcellcarcinomathepopulationrealworldandcostofillness AT marcomaruzzo renalcellcarcinomathepopulationrealworldandcostofillness AT umbertobasso renalcellcarcinomathepopulationrealworldandcostofillness AT vittorinazagonel renalcellcarcinomathepopulationrealworldandcostofillness |